Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab Richmond Pharmacokinetics and Safety Study in Healthy Subjects
NCT06291948Phase 1Completed
- Sponsor
- Laboratorios Richmond
- Start
- Aug 2022
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Armixa in rheumatoid arthritis (RA) (2 arms), sponsored by Laboratorios Richmond. Primary endpoints: Peak Serum Concentration of adalimumab at 1680 hours, Area Under the Serum Concentration-time Curve of adalimumab (ABC0-t) and 1 more. Started Aug 2022; status: completed.
02
Drugs
Armixa
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06291948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291948.